- Mark Dawson appointed Head of Roche Pharma Research and Early Development, effective 1 May 2026.
- Dawson joins from Peter MacCallum Cancer Centre, where he was Associate Director of Research.
- He is a leading expert in cancer biology, focusing on chromatin regulation and epigenetics.
- Dawson holds a medical degree from the University of Melbourne and a Ph.D. from the University of Cambridge.
Appointment Announcement
Mark Dawson, M.D., Ph.D., has been appointed as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. He will also join the Enlarged Corporate Executive Committee, based in Basel.
Professional Background
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he served as Associate Director of Research. He is recognized as a leading expert in cancer biology, particularly in chromatin regulation and epigenetics.
Academic and Professional Achievements
In addition to his clinical and research leadership roles, Dawson holds a professorial appointment at the University of Melbourne. He is an elected member of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and the European Molecular Biology Organisation (EMBO).
Education and Honors
Mark Dawson earned his medical degree from the University of Melbourne in 1999, followed by specialist training in haematology and a Ph.D. from the University of Cambridge. His career is distinguished by several prestigious international honors, including the Prime Minister’s Prize for Science (Life Scientist of the Year, 2020), the Paul Marks Prize for Cancer Research, the William Dameshek Prize from the American Society of Hematology, and recognition as a Howard Hughes International Research Scholar.
